PMID: 2125023Dec 1, 1990Paper

Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection

Genitourinary Medicine
R van LeeuwenJ M Lange

Abstract

Long-term tolerance of zidovudine treatment was retrospectively analysed in 97 patients with AIDS or AIDS-related complex. After one year of treatment 68% and after two years 87% of the patients had had at least one dose adjustment during their course of therapy. Myelotoxicity was the most common cause (58% of all cases) of dose reductions and therapy interruptions (dose adjustments). At the time of the first dose adjustment 33 patients (34%) were suffering from anaemia (Hb less than 6.0 g/dl), 20 patients (21%) from leukopenia (leukocytes less than 1.5 x 10(9], and 10 patients (10%) from thrombocytopenia (thrombocytes less than 75 x 10(9]. Fifty-six patients (57%) needed one or more blood transfusions during therapy. The median time from the start of therapy to the time of the first dose adjustment was 14 (range: 2-64) weeks in patients who had a first dose adjustment because of anaemia without co-existing leukopenia or thrombocytopenia, and 37 (range: 6-85) weeks in patients who had a first dose adjustment because of leukopenia without co-existing anaemia or thrombocytopenia (p = 0.01). Peripheral blood CD4 positive lymphocyte counts less than or equal to 100/mm3, anaemia, and CDC classification IV-C1 at the start of treatmen...Continue Reading

References

Apr 19, 1990·The New England Journal of Medicine·M C DalakasJ L Griffin
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P A FurmanH Mitsuya
Nov 3, 1989·JAMA : the Journal of the American Medical Association·M A FischlR T Schooley
Jun 1, 1989·The Annals of Thoracic Surgery·Q R StilesR J Thurer
Aug 1, 1989·Italian Journal of Neurological Sciences·M MaroldaA Bassi
Sep 17, 1988·Lancet·M HelbertA J Pinching
May 23, 1986·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control (CDC)
Feb 25, 1988·The New England Journal of Medicine·K B HymesS Karpatkin

❮ Previous
Next ❯

Citations

Jan 1, 1992·Pharmacology & Therapeutics·P H Duesberg
Jun 28, 2008·Indian Journal of Dermatology, Venereology and Leprology·Ajay SharmaYogesh Marfatia
Jun 12, 2013·Journal of Pharmaceutical Sciences·Kelen C C SoaresJennifer Dressman
Apr 1, 2015·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Kaibalya Ranjan DashS N Nayak
Apr 1, 1991·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·D C ClassenL E Stevens
Aug 6, 2004·Applied and Environmental Microbiology·Welkin H PopeJonathan King
Jul 14, 1999·Ethnicity & Health·P J CookD Honeybourne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.